Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Oncolytic viruses
Treatment H-1PV(oncolytic H-1 parvovirus)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature NS1
Official Symbol NA
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1/2
Description The presence of H-1PV RNA correlated with that of the cytotoxic viral protein NS1. But in contrast to local therapy, no NS1 could be detectedin any patient after intravenous ParvOryx injection.
PMID 28967558
Title Oncolytic H-2 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial